Funding and Investments

The company invested in a new cGMP facility located in Berlin, Germany.

The department gave Moderna $8.2 million to accelerate development of an mRNA-based Zika vaccine.

Biopharmaceutical contractors continue to invest in development, facility upgrades, technological advancement, and mergers and acquisitions.

Through the Glycoscience Program, the National Institute of Health will contribute $10 million to advance the study of carbohydrates and the compounds that interact with them.

Six grants from the NIH will help identify variants in the genome’s regulatory regions that affect disease risk, using new computational approaches.

GSK announces it will invest $95 million to launch a US-based non-profit research institute, Altius, to research technologies and approaches in understanding gene control.

Syncona and Kite Pharma announced separate investments into T-cell therapies to fight cancerous tumors.

Dalton Pharma Services announced it was awarded funding from ISTPCanada for its project to develop vaccines for respiratory syncytial virus and parainfluenza type 3.

Unum Therapeutics raised $12 million in Series A funding for its development of antibody-coupled T cell receptors (ACTRs) for the treatment of nonspecific tumor cells.

OCE and OBI partner with CQDM on $3 million inter-provincial drug discovery innovation programs.

Gene therapy, immune-oncology, and digital healthcare technologies offer investors promise for innovation investments.

Lilly1s Cyramza is the first FDA-approved treatment for advanced gastric cancer after prior chemotherapy.

Life-sciences companies continue upward momentum in 2014.

Frenzy cools as investors seeking a quick return turn elsewhere.

Caution should be taken when planning to crowdfund a biopharmaceutical startup.

The JOBS Act and FDASIA show early signs of accelerating drug development.

Early-stage companies are now embraced by buyers of new issues.

Pharmaceutical companies have stepped up gene therapy development in the wake of the approval of Glybera in 2012.

Biotech companies raise most money in 13 years.

Early-stage companies are finding alternatives to venture capital.

A handful of therapeutics have performed extremely well in 2012, but as a whole, life-sciences are still down from 2010.

A handful of therapeutics have performed extremely well in 2012, but as a whole, life-sciences are still down from 2010.

Collaborative R&D models coincide with new ways to fund translational research.

Better news about the global economy buoys life-sciences funding.

Industry announces plans for year ahead at annual JPMorgan Global Healthcare Conference.